KR20020029232A - Enteral formula suppressing the occurrence of the odor of stool and diarrhea - Google Patents
Enteral formula suppressing the occurrence of the odor of stool and diarrhea Download PDFInfo
- Publication number
- KR20020029232A KR20020029232A KR1020000060079A KR20000060079A KR20020029232A KR 20020029232 A KR20020029232 A KR 20020029232A KR 1020000060079 A KR1020000060079 A KR 1020000060079A KR 20000060079 A KR20000060079 A KR 20000060079A KR 20020029232 A KR20020029232 A KR 20020029232A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- enteral
- fructan
- patients
- diet
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 16
- 229920002670 Fructan Polymers 0.000 claims abstract description 36
- 235000016709 nutrition Nutrition 0.000 claims abstract description 35
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 17
- 201000006370 kidney failure Diseases 0.000 claims abstract description 17
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 208000019423 liver disease Diseases 0.000 claims abstract description 13
- 241000222519 Agaricus bisporus Species 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
- 239000000835 fiber Substances 0.000 claims abstract description 9
- 235000005911 diet Nutrition 0.000 claims description 30
- 230000037213 diet Effects 0.000 claims description 30
- 241000121220 Tricholoma matsutake Species 0.000 claims description 10
- 208000010643 digestive system disease Diseases 0.000 claims description 9
- 235000015872 dietary supplement Nutrition 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 230000002550 fecal effect Effects 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 13
- 208000017169 kidney disease Diseases 0.000 abstract description 12
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 235000008935 nutritious Nutrition 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 27
- 235000010755 mineral Nutrition 0.000 description 27
- 239000011707 mineral Substances 0.000 description 27
- 229940088594 vitamin Drugs 0.000 description 24
- 229930003231 vitamin Natural products 0.000 description 24
- 235000013343 vitamin Nutrition 0.000 description 24
- 239000011782 vitamin Substances 0.000 description 24
- 235000019645 odor Nutrition 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000004375 Dextrin Substances 0.000 description 18
- 229920001353 Dextrin Polymers 0.000 description 18
- 235000019425 dextrin Nutrition 0.000 description 18
- 239000008213 purified water Substances 0.000 description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 13
- 108010073771 Soybean Proteins Proteins 0.000 description 13
- 239000000787 lecithin Substances 0.000 description 13
- 229940067606 lecithin Drugs 0.000 description 13
- 235000010445 lecithin Nutrition 0.000 description 13
- 230000035764 nutrition Effects 0.000 description 13
- 229940001941 soy protein Drugs 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 108010076119 Caseins Proteins 0.000 description 11
- 102000011632 Caseins Human genes 0.000 description 11
- 239000000828 canola oil Substances 0.000 description 10
- 235000019519 canola oil Nutrition 0.000 description 10
- 238000001631 haemodialysis Methods 0.000 description 10
- 230000000322 hemodialysis Effects 0.000 description 10
- 239000010977 jade Substances 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 239000005018 casein Substances 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 210000002429 large intestine Anatomy 0.000 description 8
- 229940071440 soy protein isolate Drugs 0.000 description 8
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 235000019743 Choline chloride Nutrition 0.000 description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 102000014171 Milk Proteins Human genes 0.000 description 7
- 108010011756 Milk Proteins Proteins 0.000 description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 7
- 229930003451 Vitamin B1 Natural products 0.000 description 7
- 229930003779 Vitamin B12 Natural products 0.000 description 7
- 229930003471 Vitamin B2 Natural products 0.000 description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- 229930003448 Vitamin K Natural products 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 7
- 229960002079 calcium pantothenate Drugs 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 7
- 229960003178 choline chloride Drugs 0.000 description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 7
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 7
- 229910000365 copper sulfate Inorganic materials 0.000 description 7
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 7
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 7
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 7
- 239000011790 ferrous sulphate Substances 0.000 description 7
- 235000003891 ferrous sulphate Nutrition 0.000 description 7
- 229960000304 folic acid Drugs 0.000 description 7
- 235000019152 folic acid Nutrition 0.000 description 7
- 239000011724 folic acid Substances 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 7
- 229940099596 manganese sulfate Drugs 0.000 description 7
- 239000011702 manganese sulphate Substances 0.000 description 7
- 235000007079 manganese sulphate Nutrition 0.000 description 7
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 7
- 235000021239 milk protein Nutrition 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- 235000001968 nicotinic acid Nutrition 0.000 description 7
- 239000011664 nicotinic acid Substances 0.000 description 7
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 7
- 239000001103 potassium chloride Substances 0.000 description 7
- 235000011164 potassium chloride Nutrition 0.000 description 7
- 239000001508 potassium citrate Substances 0.000 description 7
- 229960002635 potassium citrate Drugs 0.000 description 7
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 7
- 235000011082 potassium citrates Nutrition 0.000 description 7
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 7
- 229940108325 retinyl palmitate Drugs 0.000 description 7
- 235000019172 retinyl palmitate Nutrition 0.000 description 7
- 239000011769 retinyl palmitate Substances 0.000 description 7
- 229960002477 riboflavin Drugs 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229960003495 thiamine Drugs 0.000 description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 7
- 235000010374 vitamin B1 Nutrition 0.000 description 7
- 239000011691 vitamin B1 Substances 0.000 description 7
- 235000019163 vitamin B12 Nutrition 0.000 description 7
- 239000011715 vitamin B12 Substances 0.000 description 7
- 235000019164 vitamin B2 Nutrition 0.000 description 7
- 239000011716 vitamin B2 Substances 0.000 description 7
- 235000019158 vitamin B6 Nutrition 0.000 description 7
- 239000011726 vitamin B6 Substances 0.000 description 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 7
- 235000005282 vitamin D3 Nutrition 0.000 description 7
- 239000011647 vitamin D3 Substances 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 235000019168 vitamin K Nutrition 0.000 description 7
- 239000011712 vitamin K Substances 0.000 description 7
- 150000003721 vitamin K derivatives Chemical class 0.000 description 7
- 229940011671 vitamin b6 Drugs 0.000 description 7
- 229940021056 vitamin d3 Drugs 0.000 description 7
- 229940046010 vitamin k Drugs 0.000 description 7
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 7
- 229910000368 zinc sulfate Inorganic materials 0.000 description 7
- 229960001763 zinc sulfate Drugs 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 6
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000003531 protein hydrolysate Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 4
- 229940078499 tricalcium phosphate Drugs 0.000 description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000006180 nutrition needs Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 150000003464 sulfur compounds Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- SCWWKKUJPHRBRV-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;sodium Chemical compound [Na].NCCCC[C@H](N)C(O)=O SCWWKKUJPHRBRV-JEDNCBNOSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 229940080237 sodium caseinate Drugs 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- -1 12.02 g Proteins 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 경장 영양식을 섭취한 경우에 분변취 및 설사발생을 방지 또는 최소화 하기 위해서, 송이버섯(Agaricus bisporus)과육의 친수성 용매추출물과 프럭탄 식이섬유(fructan fiber)를 포함하는 경장영양식을 제공하며, 특히, 신부전증환자, 신장병환자, 만성간질환자, 당뇨병환자용 또는 소화기질환자용 영양식과 같은 환자용 특수영양식품 또는 건강보조식품에 관한 것이다.The present invention provides an enteral diet comprising hydrophilic solvent extracts of fructose and fructan fiber in order to prevent or minimize the occurrence of fecal odor and diarrhea when ingested enteric nutrition. In particular, the present invention relates to special nutritional supplements or dietary supplements for patients, such as nutritional supplements for patients with renal failure, kidney disease, chronic liver disease, diabetes or digestive disease.
일반적으로 환자식은 대한민국 식품공전에서 특수영양식품으로 분류되어 주로 경구 또는 경관급식 용으로 제조되어 사용되고 있다. 종래까지 환자를 위한 영양식은 대한민국 특허공고 제97-005903호에 기재된 바와 같이, 특정환자의 질병에 관련하여 영양성분의 함량을 조정하여 환자의 영양요구량을 충족시키는데 주안점을 두고 있으나 설사와 변비발생을 억제하거나 분변취의 발생을 억제하는 기능은 고려된 사실이 없었다.In general, the patient food is classified as a special nutritional food at the Korea Food Fair and is mainly manufactured and used for oral or landscape feeding. Conventionally, nutritional formula for patients has been focused on satisfying the nutritional requirements of patients by adjusting the content of nutrients related to diseases of specific patients, as described in Korean Patent Publication No. 97-005903. The function of inhibiting or inhibiting the occurrence of fecal odor has not been considered.
특히 설사의 발생은 여러 종류의 항생제 투여에 의해서 경구, 경관급식 환자에게 아주 빈번하게 일어나는 부작용이며 특히 경관급식 환자의 경우 설사 증상이 항문주위의 피부 손상을 일으킬 수 있다. 그리고 장기간 입원 중인 신경외과 환자의 경우에는 환자 스스로의 의식이 없어 음식물 섭취와 대,소변의 처리 등을 타인의 받아야만 한다. 그러나 환자의 분변취와 체취의 발생은 환자 보호자의 간병에 많은 불편을 줄 수 있다. 그러한 분변취는 수술 후 회복환자와 같이 고단백식을 섭취하는 경우 더욱 강하게 발생한다.In particular, the occurrence of diarrhea is a very frequent side effect of oral or cervical feeding patients by the administration of various antibiotics, especially in the cervical feeding patients, diarrhea may cause skin damage around the anus. In the case of neurosurgery patients who have been hospitalized for a long time, the patient has no consciousness of himself and must receive other people's food intake and treatment of urine and urine. However, the occurrence of fecal odor and body odor can cause a lot of inconvenience for the caregiver of the patient. Such fecal odor occurs more strongly when a high protein diet is consumed, such as after recovery from surgery.
이러한 문제점을 해결하기 위해서 본 발명의 발명자는 기존의 기술에서 일어나는 문제점들을 해결하기 위해서 연구한 결과 기존의 경장영양식보다 더 좋은 영양공급뿐만 아니라 경장영양식을 이용하는 환자나 노약자의 생리적 특성을 고려하여 본 발명을 완성하였다.In order to solve these problems, the inventors of the present invention have studied to solve the problems occurring in the existing technology, and as a result of considering the physiological characteristics of patients or the elderly using the enteric culture as well as better nutrition than the existing enteral culture, Was completed.
본발명은 송이버섯(Agaricus bisporus)과육의 친수성 용매추출물과 프럭탄 식이섬유(fructan fiber)를 포함하는 경장영양식을 제공하여 분변취의 제거 및 설사를 방지하고 영양적으로 우수한 액상 또는 분말 경장영양식을 제공하고자 한다.The present invention provides an enteric diet comprising hydrophilic solvent extract and fructan fiber of Agaricus bisporus flesh to prevent fecal odor and prevent diarrhea and to provide nutritionally superior liquid or powder enteric diet. To provide.
본발명의 또다른 목적은 송이버섯(Agaricus bisporus)과육의 친수성 용매추출물과 프럭탄 식이섬유(fructan fiber)를 포함하는 경장영양식을 제공하여 분변취의 제거 및 설사를 방지하고 영양적으로 우수한 액상 또는 분말의 신부전증환자, 신장병환자, 만성간질환자, 당뇨병환자용 또는 소화기질환자용 영양식과 같은 환자용 특수영양식품 또는 건강보조식품을 제공하는 것이다.Another object of the present invention is to provide an enteric diet comprising hydrophilic solvent extracts of Agaricus bisporus flesh and fructan fiber to prevent fecal odor and prevent diarrhea, It is to provide special nutritional supplements or health supplements for patients, such as nutritional foods for patients with kidney failure, kidney disease, chronic liver disease, diabetes or digestive disease.
본 발명은 경장 영양식을 섭취한 경우에 분변취 및 설사발생을 방지 또는 최소화하기 위해서, 양송이(Agaricus bisporus)과육의 친수성 용매추출물과 프럭탄 식이섬유(fructan fiber)를 포함하는 경장영양식을 제공하며, 특히, 경관급식용 경장영양식과 신부전증환자, 신장병환자, 만성간질환자, 당뇨병환자용 또는 소화기질환자용 영양식과 같은 환자용 특수영양식품에 관한 것이다.The present invention provides an enteral diet comprising a hydrophilic solvent extract of fructose (Agaricus bisporus) flesh and fructan fiber in order to prevent or minimize the occurrence of fecal odor and diarrhea when ingested enteric nutrition. In particular, it relates to cervical feeding and special nutritional products for patients such as renal failure patients, kidney disease patients, chronic liver disease patients, diabetes patients or nutritional foods for digestive diseases.
본발명의 경장영양식은 분말로 제공되어 직접 사용시에 가수하여 섭취할 수도 있고, 액상으로 제공될 수 있다.Enteral culture of the present invention is provided as a powder may be ingested by direct hydrolysis, or may be provided in liquid form.
본 발명은 경구 또는 경관급식을 하여야 하는 특수영양식품과 특정용도식품의 경우 가장 문제가 되는 부작용이 설사와 분변취의 발생을 최소화할 수 있는 제품이다. 본 발명에서 사용하는 프럭탁 식이섬유 (fructan fiber)는 설사와 변비의 발생을 방지하기 위한 것이다. 기존의 제품에서 빈번하게 발생하는 설사와 변비가 발생하며 특히 환자식의 경우에는 환자는 운동량이 적고, 여러 종류의 항생제 투여에 의해서 경구, 경관급식 환자에게 아주 빈번하게 일어나며, 특히 장기간 동안 경관급식 환자의 경우 설사 증상으로 인해 이 항문주위의 피부 손상을 일으킬 수도 있다.The present invention is a product that can minimize the occurrence of diarrhea and fecal odor is the most problematic side effects for special nutritional foods and specific foods to be oral or landscape feeding. The fructan fiber used in the present invention is to prevent the occurrence of diarrhea and constipation. Diarrhea and constipation occur frequently in the existing products, especially in the case of patient type, the patient has low exercise volume, and it occurs very frequently in the oral and cervical feeding patients by the administration of various kinds of antibiotics. Diarrhea may cause skin damage around the anus.
이와 같은 문제점은 프럭탄 식이섬유를 1일 4-35g을 섭취하도록 하면 예방할 수 있다. 분말 경장영양식인 경우에 프럭탄 식이섬유를 100g 당 2.5g 내지 8g로 함유하고, 액상 경장영양식인 경우 100ml 당 0.6g 내지 2g을 함유하고 프럭탄 식이섬유를 100ml 당 0.04g 내지 0.016g을 함유하는 것이 바람직하다.This problem can be prevented by taking 4-35g of fructan dietary fiber per day. In case of powdered enteral culture, fructan dietary fiber contains 2.5g to 8g per 100g, in case of liquid enteral culture, it contains 0.6g to 2g per 100ml and fructane dietary fiber contains 0.04g to 0.016g per 100ml It is preferable.
이러한 특성을 부여할 수 있는 프럭탄 식이섬유는 이눌린에서 유래된 수용성 식이섬유로서 중합도는 2-60 정도의 것이 적절하다. 본 발명에서 제안하는 함량의 프럭탄 식이섬유는 사람의 소화장관 소화효소에 의해서 잘 가수분해되지 않고 대장에도달하여 비교적 낮은 수준에서도 유익한 유산균 속인 비피도박테리아의 균수를 선택적으로 증진하는 효과가 있다(Bouhnik 등, Gasteroenterology. 106:A598, 1994; Buddington 등, Am. J. Clin. Nutr. 63:709, 1996; Gibson 등, Gastroenterology. 108:975, 1995; Kleessen 등, Am. J. Clin. Nutr. 65:1397, 1997; Mitsuoka 등, Die Nahrung 31:426, 1987; Williams 등, Microb. Ecol. Health Dis. 7:91, 1994). 그리고 배변횟수와 변의 굳기에 대한 개선이 명확하게 나타났다고 하였다(Sobata 등, Nutrition. 13:21, 1997). 이러한 효과는 유산균에 의해서 프럭탄 식이섬유가 분해되어 생산되는 단쇄지방산이 수분 흡수량의 증가를 유도하여 분변중 수분 함량을 감소시킨데 기인한다고 보고되고 있다(Bowling 등, Lancet. 342:1266, 1993; Sobata 등, Nutrition. 13:21, 1997).The fructan dietary fiber which can impart such a property is a water-soluble dietary fiber derived from inulin, and a polymerization degree of about 2-60 is appropriate. The fructan dietary fiber of the present invention does not hydrolyze well by human digestive tract digestive enzymes and reaches the large intestine, thereby selectively increasing the number of Bifidobacteria bacteria, which are beneficial lactic acid bacteria at relatively low levels. Bouhnik et al., Gasteroenterology. 106: A598, 1994; Buddington et al., Am. J. Clin. Nutr. 63: 709, 1996; Gibson et al., Gastroenterology. 108: 975, 1995; Kleessen et al., Am. J. Clin. Nutr. 65: 1397, 1997; Mitsuoka et al., Die Nahrung 31: 426, 1987; Williams et al., Microb. Ecol. Health Dis. 7:91, 1994). In addition, improvements in the frequency of bowel movements and stiffness of stool were evident (Sobata et al., Nutrition. 13:21, 1997). This effect is reported to be due to the decrease in the water content of feces by short-chain fatty acids produced by the decomposition of fructan dietary fiber by lactic acid bacteria (Bowling et al., Lancet. 342: 1266, 1993; Sobata et al., Nutrition. 13:21, 1997).
본 발명에서 사용한 중합도 2에서 60의 프럭탄 식이섬유는 다른 수용성 식이섬유와 비교해서 다음과 같은 특징이 있다. 즉, 소화물의 장관 통과 시간을 단축시키며 장의 운동성을 향상시켜 배변회수를 증가시킬 뿐만 아니라 설사를 개선하는 기능을 부여하며(Kleessen 등, Am. J. Clin. Nutr. 65:1397, 1997), 대장에서 유익한 미생물인 비피도박테리아의 성장을 선택적으로 촉진시켜 항생제 투여에 의해 유익한 장내 미생물 성장 억제에 의해 발생할 수 있는 설사를 예방한다.(Gibson 등, Gastroenterology 108:975, 1995); Gibson과 Robert, J. Nutr. 125:1401, 1995), 대장에서 프럭탄 식이섬유가 분해되어 단쇄지방산과 젖산의 생산을 증가시켜 대장에서 칼슘, 마그네슘, 철, 아연 등의 미네랄의 흡수를 용이하며(Coudray 등, Eur. J. Clin. Nutr.51: 375, 1997), 대장에서 미네랄이 이온화되면 담즙산 또는 지방산과 염을 형성하여 담즙산과 단쇄지방산에 의한 결장세포의 손상을 방지해 준다(Coudray 등, Eur. J. Clin. Nutr.51:375, 1997).The fructan dietary fiber of 60 in the polymerization degree 2 used by this invention has the following characteristics compared with other water-soluble dietary fiber. In other words, it shortens the intestinal transit time of digestive products and improves bowel motility to increase the number of bowel movements and to improve diarrhea (Kleessen et al., Am. J. Clin. Nutr. 65: 1397, 1997). Selectively promotes the growth of a beneficial microorganism, Bifidobacteria, to prevent diarrhea that can be caused by the suppression of beneficial intestinal microbial growth by antibiotic administration (Gibson et al., Gastroenterology 108: 975, 1995); Gibson and Robert, J. Nutr. 125: 1401, 1995), which breaks up the fructan dietary fiber in the large intestine, increasing the production of short-chain fatty acids and lactic acid, thereby facilitating the absorption of minerals such as calcium, magnesium, iron and zinc in the large intestine (Coudray et al., Eur. J. Clin. Nutr. 51: 375, 1997), the ionization of minerals in the large intestine forms salts with bile acids or fatty acids to prevent damage to colon cells by bile acids and short-chain fatty acids (Coudray et al., Eur. J. Clin. Nutr). 51: 375, 1997).
또한, 본 발명에서 분변취 발생의 방지 및 억제를 위해서 양송이(champignon mushroom)과육의 친수성용매 추출물(학명 : Agaricus bisporus)을 포함하였다.In addition, in the present invention, the hydrophilic solvent extract (champion name: Agaricus bisporus) of the mushroom (champignon mushroom) flesh for the prevention and suppression of the generation of feces.
본 발명에서 분변취 발생억제 물질은 송이버섯의 친수성 용매 추출물로서 Bio-M(상표명,일본 리콤사) 혹은 샴피니온이라고도 하며 사용량은 송이버섯추출물의 함량에 따라서 1일 0.5 내지 2.0g을 섭취하도록 한다. 분말 경장영양식인 경우에 상기 송이버섯 과육의 친수성 용매추출물(Bio-M)을 100g 당 0.1 내지 0.4g로 함유하고, 액상 경장영양식인 경우 100ml 당 0.6g 내지 2g을 함유하는 것이 바람직하다.Fecal odor generation inhibitor in the present invention is a hydrophilic solvent extract of Matsutake mushroom also called Bio-M (trade name, Japan Ricom Co.) or Champignion and the amount of 0.5 to 2.0 g per day depending on the content of Matsutake extract do. In the case of powder enteral culture, the hydrophilic solvent extract (Bio-M) of the pine mushroom flesh is preferably contained in 0.1 to 0.4 g per 100 g, and in the case of liquid enteral culture, it contains 0.6 g to 2 g per 100 ml.
사람에 대해서 Bio-M의 분변취 발생억제효과를 시험하기 위해서 송이버섯추출물의 함량에 따라서 1일 0.5 내지 2.0g을 섭취한 결과 분변 중 암모니아, 메칠메르캅탄, 메틸아민, 황화수소 등의 함량이 급격히 낮아지는 동시에 혈중 암모니아의 농도도 역시 낮출 수 있었다고 보고하고 있다(浜屋忠生. 食品と開發. 30:41, 1995; 何部二郞. 弟 36回 東北臨床衛生檢査學會 發表內容, 1995).In order to test the effect of bio-M fecal odor on humans, ingestion of 0.5 to 2.0 g per day depending on the content of pine mushroom extract resulted in a rapid increase in the contents of ammonia, methylmercaptan, methylamine and hydrogen sulfide in feces. At the same time, it has been reported that the concentration of ammonia in blood could also be lowered (浜 屋 忠 生. 食品 と 開發. 30:41, 1995; 何 部 二 郞. 弟 36 回, 1995 表 內容, 1995).
따라서 본 발명에서는 환자의 분변취 발생을 최소화 시키기 위해서 Bio-M 분말을 0.5 내지 2.0g 함유하는 경장영양식 제조에 관한 내용을 제공하고져 한다.Therefore, in the present invention, to minimize the generation of fecal odor of the patient to provide information on the preparation of enteral diet containing 0.5 to 2.0g Bio-M powder.
송이버섯추출물의 소취 메카니즘은 소화기관에 따라 세가지로 나눠질 수 있으며, 몸에서 나타나는 악취가 발생하지 않게 하는 기능이 있기 때문에 이러한 성분을 일정량 함유하고 있는 경장영양식을 섭취하여도 거의 동일한 효과가 있다.The deodorant mechanism of pine mushroom extract can be divided into three types according to the digestive organs, and since it has a function of preventing the odor appearing in the body, it is almost the same effect even when the enteric diet containing a certain amount of these ingredients is ingested.
첫째, 구강, 식도, 위, 소장에서 악취는 각각 구강내의 균에 의한 단백질의 분해,음식물에 함유되어 있는 효소에 의한 분해 그리고 구강, 위, 소장에서 소화효소에 의한 분해 작용에 의해서 메틸메르캅탄과 황화수소 등의 휘발성유황화합물이 발생한다. 상기 양송이 친수성 추출물의 구강, 식도, 위 그리고 소장에서 발생하는 악취 억제 기작은 여러 종류의 폴리페놀에 의한 부가반응에 의해서 휘발성유황화합물이 비휘발성으로 변화되어 악취성분이 제거된다. 둘째, 분변 및 소화물에서의 발생은 대장에서는 장내세균에 의한 대사산물과 소화되지 않은 영양분 중에 함유되어 있는 효소에 의한 단백질 분해작용에 의해 메틸메르캅탄, 디메틸설파이드, 암모니아, 아민, 황화수소 등 약 100종류의 휘발성유황화합물에 의해서 기인한다. 사람에게 임상실험한 결과 상기 송이버섯과육 친수성 용매추출물은 대장에서 발생하는 대사산물의 생산을 억제하여 분변취의 발생을 낮추어준다는 사실이 확인되었다(何部二郞. 弟 36回 東北臨床衛生檢査學會 發表內容, 1995).First, odors in the oral cavity, esophagus, stomach, and small intestine may be affected by methyl mercaptan and the digestion of proteins by bacteria in the oral cavity, by enzymes in food, and by digestive enzymes in the oral cavity, stomach, and small intestine. Volatile sulfur compounds such as hydrogen sulfide are generated. Odor suppression mechanisms occurring in the oral cavity, esophagus, stomach and small intestine of the mushroom hydrophilic extract are changed to non-volatile volatile sulfur compounds by addition reactions of various types of polyphenols to remove odor components. Second, about 100 types of feces and digestions occur in the large intestine such as methyl mercaptan, dimethyl sulfide, ammonia, amine and hydrogen sulfide by proteolysis by metabolites of intestinal bacteria and enzymes contained in undigested nutrients. Is caused by volatile sulfur compounds. As a result of clinical trials in humans, it was confirmed that the pine mushroom flesh hydrophilic solvent extract lowers the incidence of fecal odor by inhibiting the production of metabolites in the large intestine (何 部 二 郞. 弟 36 回 東北 臨 床 衛生 檢査 學會發表 內容, 1995).
셋째, 호흡을 통한 악취의 발생은 대장내의 악취성분이 장관으로부터 혈액으로 흡수된 다음 입으로 배출되어 발생한다. 악취의 제거 기작은 대장내의 악취성분의 농도를 억제함으로써 장관으로부터 혈액으로 흡수되지 않는다.Third, the occurrence of odor through breathing occurs when the odor component in the large intestine is absorbed into the blood from the intestine and then discharged into the mouth. The mechanism of eliminating malodor is not absorbed into the blood from the intestine by suppressing the concentration of malodorous components in the large intestine.
본 발명의 경장영양식은 특수영양식품, 예컨대 신부전증환자, 신장병환자, 만성간질환자, 당뇨병환자용 또는 소화기질환자용 영양식과 같은 환자용 특수영양식품의 개발에 대해서 관한 것으로서 각 질환에 대한 제품의 영양학적 특성 뿐만아니라 환자의 삶의 질을 향상시킬 수 있도록 설사의 발생을 예방하고 그리고 분변취를 포함한 악취를 제거할 수 있는 경장영양식을 개발하는 것으로서 제품의 조성은 다음과 같다.The enteral nutrition of the present invention relates to the development of special nutritional products, such as nutritional foods for patients such as kidney failure, kidney disease, chronic liver disease, diabetic or digestive disease, as well as nutritional characteristics of the product for each disease Rather, it is to develop an enteral diet that can prevent the occurrence of diarrhea and remove odors, including fecal odor, to improve the quality of life of patients.
1) 분말 일반경장영양식1) Powder General Entering Culture
케이신(casein) 또는 케이신나트륨(sodium caseinate)과 케이신가수분해물 (enzymatic casein hydrolysate), 17.17g, 덱스트린 46.1g, 설탕 15.0g, 프락탄식이섬유 6.45g, 옥배유 10.58g, MCT 유 2.64g, 대두레시친 0.3g, Bio-M 0.133g을 정제수에 용해한 후 표 1의 비타민과 미네랄을 첨가하여 살균, 균질, 농축, 분무건조하여 일반인의 영양보충과 환자들의 영양요구량을 완전히 충족할 수 있는 분말 경장영양식을 제조한다.Casein or sodium caseinate and enzymatic casein hydrolysate, 17.17 g, dextrin 46.1 g, sugar 15.0 g, fructan dietary fiber 6.45 g, jade oil 10.58 g, MCT oil 2.64 g , 0.3g soy lecithin and 0.133g Bio-M dissolved in purified water and added to the vitamins and minerals of Table 1 to sterilize, homogenize, concentrate and spray dry to fully satisfy the nutritional needs of the general public and the nutritional requirements of patients. Prepare enteric culture.
카세인 또는 카세인나트륨(sodium caseinate)과 카세인가수분해물(enzymatic casein hydrolysate), 12.02g, 분리대두단백질 또는 분리대두단백 분해물 5.15g, 덱스트린 46.1g, 설탕 15.0g, 프락탄식이섬유 6.45g, 옥배유 10.58g, MCT 유 2.64g, 대두 레시틴 0.3g, Bio-M 0.133g을 정제수에 용해한 후 표 2의 비타민과 미네랄을 첨가하여 살균, 균질, 농축, 분무건조하여 주요 원료로 하여 첨가물로서 상기 표 1과 같이 혼합하여 균질, 농축, 분무건조하여 일반인의 영양보충과 환자들의 영양요구량을 완전히 충족할 수 있는 분말 경장영양식을 제조한다Casein or sodium caseinate and enzymatic casein hydrolysate, 12.02 g, soy protein or soy protein isolate 5.15 g, dextrin 46.1 g, sugar 15.0 g, fructan dietary fiber 6.45 g, jade oil 10.58 g , MCT oil 2.64g, soy lecithin 0.3g, Bio-M 0.133g dissolved in purified water and then added vitamins and minerals of Table 2 as sterilization, homogeneous, concentrated, spray-drying as the main raw material as shown in Table 1 as an additive By mixing, homogenizing, condensing and spray-drying to prepare a powder enteric diet that can fully satisfy the nutritional needs of the general public and the nutritional requirements of patients.
2) 액상 경장영양식2) Liquid Enteral Culture
유단백질(케이신 또는 케이신나트륨과 케이신가수분해물), 식물성단백질(분리대두단백질 또는 분리대두단백 분해물)을 단일 단백질원 혹은 유단백질과 식물성단백질 70:30 혼합물을 4.3%, 덱스트린 11.53%, 설탕 3.75%, 프락탄식이섬유 1.61%, 옥배유 2.65%, MCT 유 0.66%, 대두레시친 0.1%, Bio-M 0.04%의 비율로 정제수로 용해하여 100ml로 최종량을 조정한 다음 표 2와 같이 비타민과 미네랄을 첨가하여 균질, 포장, 리토르트 멸균 또는 살균하여 일반인의 영양보충과 환자들의 영양요구량을 완전히 충족할 수 있는 액상 경장영양식을 제조한다.Milk protein (Kysine or Casein Sodium and Kesin Hydrolysates), vegetable protein (Isolated Soy Protein or Soy Protein Isolate) can be a single protein source or 4.3% mixture of milk protein and vegetable protein 70:30, Dextrin 11.53%, Sugar 3.75 %, Fructan dietary fiber 1.61%, jade oil 2.65%, MCT oil 0.66%, soy lecithin 0.1%, Bio-M 0.04% dissolved in purified water to adjust the final amount to 100ml and then vitamins and minerals as shown in Table 2 To add a homogeneous, packaged, retort sterilized or sterilized to prepare a liquid entertaining diet that can fully meet the nutritional needs of the general public and the nutritional requirements of patients.
3) 경관 급식용 분말 경장영양식3) Powder feed for landscape feeding
케이신나트륨 또는 분리대두단백 또는 케이신나트륨과 분리대두단백 70:30 혼합물 18.44g, 덱스트린 64.25g, 프락탄식이섬유 6.45g, 옥배유 10.6g, MCT 유 2.7g, 레시친 0.3g, Bio-M 0.133g을 정제수에 용해한 후 표 3에서와 같이 비타민과 미네랄을 첨가하여 살균, 균질, 농축 그리고 분무건조하여 경관급식(tube feeding)용 분말 경장영양식 제품을 제조한다.Soybean Caine or Soy Protein Isolate or Soy Protein Isolate Soy Protein 70:30 18.44g, Dextrin 64.25g, Frutan Dietary Fiber 6.45g, Oxygen Oil 10.6g, MCT Oil 2.7g, Lecithin 0.3g, Bio-M 0.133 After dissolving g in purified water, sterilized, homogenized, concentrated and spray-dried by adding vitamins and minerals as shown in Table 3 to prepare a powder enteral nutritional product for tube feeding.
4) 경관급식용 액상 경장영양식4) Liquid entertaining food for landscape feeding
케이신나트륨, 분리대두단백 또는 케이신나트륨과 분리대두단백 70:30 혼합물 4.61%, 덱스트린 16.06%, 식이섬유 1.61%, 옥배유 2.65%, MCT 유 0.68%, 레시친 0.1%, 프락탄식이섬유 1.61%, Bio-M 0.04%를 정제수에 용해한 다음 표 3과 같이 비타민과 미네랄을 첨가하고 전체 용량을 100ml가 되게 조정하여 균질, 포장, 리토르트 멸균 또는 살균하여 경관급식(tube feeding)용 액상 경장영양식을 제품을 제조한다.Soy Casein Soy Protein, Soy Protein Isolate or Soy Protein Isolate Soy Protein 70:30 4.61%, Dextrin 16.06%, Dietary Fiber 1.61%, Oxygen Oil 2.65%, MCT Oil 0.68%, Lecithin 0.1%, Fractan Dietary Fiber 1.61% , Dissolve 0.04% of Bio-M in purified water, add vitamins and minerals as shown in Table 3, adjust the total volume to 100ml, and homogenize, package, retort sterilize or sterilize the liquid enteral culture for tube feeding. Manufacture the product.
5) 신부전증 환자용 분말 경장영양식5) Powder enteral diet for patients with renal failure
유단백질(케이신 또는 케이신나트륨과 케이신가수분해물), 식물성단백질(분리대두단백질 또는 분리대두단백 분해물)을 단일 단백질원 혹은 유단백질과 식물성단백질 70:30 혼합물 9.48g, 덱스트린 60.4g, 카놀라유 10.64g, 옥배유 15.95g, 레시친 0.35g, 프락탄식이섬유 6.45g, Bio-M 0.133g을 정제수에 용해한 후 표 4와 같이 비타민과 미네랄을 첨가하여 살균, 균질, 농축, 분무건조하여 혈액투석을 행하지 않는 신부전증 환자용 분말 경장영양식 제품을 제조한다.Milk protein (Kysine or Casein Sodium and Kesin Hydrolysate), vegetable protein (Isolated Soy Protein or Soy Protein Isolate) can be a single protein source or 9.48g of milk protein and vegetable protein 70:30 mixture, 60.4g dextrin, 10.64g canola oil , 15.95 g of jade oil, 0.35 g of lecithin, 6.45 g of fructan dietary fiber, and 0.133 g of Bio-M were dissolved in purified water and added with vitamins and minerals as shown in Table 4 to disinfect, homogenize, concentrate, and spray dry them to avoid hemodialysis. Prepare a powder enteral nutrition product for patients with renal failure.
6) 혈액투석을 하지 않는 신부전증 환자용 액상 경장영양식6) Liquid enteral culture for patients with renal failure without hemodialysis
유단백질(케이신 또는 케이신나트륨과 케이신가수분해물), 식물성단백질(분리대두단백질 또는 분리대두단백 분해물)을 단일 단백질원 혹은 유단백질과 식물성 단백질 70:30 혼합물 2.35%, 덱스트린 15.1%, 카놀라유 2.66%, 옥배유 3.99%, 레시친 0.1%, 프락탄식이섬유 1.61%, Bio-M 0.04%을 정제수에 용해하고 표 4와 같이 비타민과 미네랄을 첨가하여 전체 용량을 100ml로 조정한 후에 균질, 포장, 리토르트 멸균 또는 살균하여 투석을 행하지 않는 신부전증 환자를 위한 액상경장영양식을 제조한다.Milk protein (casein or casein and casein hydrolysates) and vegetable protein (separated soy protein or soy protein isolate) can be derived from a single protein source or a mixture of milk protein and vegetable protein 70:30 2.35%, dextrin 15.1%, canola oil 2.66% , Jade oil 3.99%, lecithin 0.1%, fructan dietary fiber 1.61%, Bio-M 0.04% dissolved in purified water and added to vitamins and minerals as shown in Table 4 to adjust the total volume to 100ml homogeneous, packaging, retort A liquid enteral culture is prepared for patients with renal failure who do not undergo dialysis by sterilization or sterilization.
7) 혈액투석을 하는 신부전증 환자용 분말 경장영양식7) Powder enteral form for patients with renal failure with hemodialysis
유단백질 혼합물(가수분해유청단백질과 케이신나트륨 50:50)22.81g ,덱스트린 46.72g, 카놀라유 10.82g, 옥배유 16.24g, 레시친 0.35g, 프락탄식이섬유 6.45g, Bio-M 0.133g을 정제수에 용해하여 잘 용해한 다음 표 4와 같이 비타민과 미네랄을 첨가하여 살균, 균질, 농축, 분무건조하여 혈액 투석을 행하고 있는 신부전증 환자용 분말경장영양식을 제조한다.Milk protein mixture (hydrolysed whey protein and sodium kesin 50:50) 22.81 g, dextrin 46.72 g, canola oil 10.82 g, jade oil 16.24 g, lecithin 0.35 g, fructan dietary fiber 6.45 g, Bio-M 0.133 g dissolved in purified water Dissolve well, and then add vitamins and minerals as shown in Table 4 to prepare a powder enteral diet for renal failure patients who are undergoing hemodialysis by sterilization, homogenization, concentration, and spray drying.
또는, 케이신나트륨과 가수분해케이신 50:50 혼합물 22.81g, 덱스트린 46.72g, 카놀라유 10.82g, 옥배유 16.24g, 레시친 0.35g, 프락탄식이섬유 6.45g, Bio-M 0.133g을 정제수에 용해한 다음 표 4와 같이 비타민과 미네랄을 첨가하여 살균, 균질, 농축, 분무건조하여 혈액 투석을 행하고 있는 신부전증 환자용 분말경장영양식을 제조한다.Alternatively, 22.81 g of a mixture of sodium and lysine 50:50, 46.72 g of dextrin, 10.82 g of canola oil, 16.24 g of jade oil, 0.35 g of lecithin, 6.45 g of fructan dietary fiber, and 0.133 g of Bio-M were dissolved in purified water. As shown in Table 4, sterilized, homogenized, concentrated and spray-dried by adding vitamins and minerals to prepare a powder enteral diet for renal failure patients undergoing hemodialysis.
8) 혈액투석 신장병 환자용 분말 경장영양식8) Powder Enteral Diet for Hemodialysis Kidney Disease Patients
케이신나트륨과 가수분해 대두단백질 50:50 혼합물 22.81g, 덱스트린 46.72g, 카놀라유 10.82g, 옥배유 16.24g, 레시친 0.35g, 프락탄식이섬유 6.45g, Bio-M 0.133g을 정제수에 용해하여 교반하고 여기에 표 4와 같이 비타민과 미네랄을 첨가하여 살균한 다음 농축하고 분무건조하여 혈액투석 신장병 환자용 분말경장영양식을 제조한다.Sodium kesin and hydrolyzed soy protein 50:50 22.81 g, dextrin 46.72 g, canola oil 10.82 g, jade oil 16.24 g, lecithin 0.35 g, fructan dietary fiber 6.45 g, Bio-M 0.133 g, dissolved in purified water and stirred Here, as shown in Table 4, sterilized by adding vitamins and minerals, and then concentrated and spray-dried to prepare a powder enteral diet for hemodialysis kidney disease patients.
또한, 분리대두단백질과 유청단백질가수분해물 50:50 혼합물 22.81g, 덱스트린 46.72g, 카놀라유 10.82g, 옥배유 16.24g, 레시친 0.35g, 프락탄식이섬유 6.45g, Bio-M 0.133g을 정제수에 용해하여 교반하고 여기에 표 4와 같이 비타민과 미네랄을 첨가하여 살균한 다음 농축하고 분무건조하여 혈액투석 신장병 환자용 분말경장영양식을 제조한다.In addition, 22.81 g of the soy protein and whey protein hydrolysate 50:50 mixture, dextrin 46.72 g, canola oil 10.82 g, jade oil 16.24 g, lecithin 0.35 g, fructan dietary fiber 6.45 g, and Bio-M 0.133 g were dissolved in purified water. After stirring and sterilizing by adding vitamins and minerals as shown in Table 4, concentrated and spray-dried to prepare a powder enteral diet for hemodialysis kidney disease patients.
또다른 일례로, 분리대두단백질과 대두단백질가수분해물 50:50 혼합물 22.81g, 덱스트린 46.72g, 카놀라유 10.82g, 옥배유 16.24g, 레시친 0.35g, 프락탄식이섬유 6.45g, Bio-M 0.133g을 정제수에 용해하여 교반하고 여기에 표 4와 같이 비타민과미네랄을 첨가하여 살균한 다음 농축하고 분무건조하여 혈액투석 신장병 환자용 분말 경장영양식을 제조한다.As another example, the purified soy protein and soy protein hydrolysate 50:50 mixture 22.81 g, dextrin 46.72 g, canola oil 10.82 g, jade oil 16.24 g, lecithin 0.35 g, fructan dietary fiber 6.45 g, Bio-M 0.133 g purified water Dissolve in and stir, add vitamins and minerals as shown in Table 4, sterilize, concentrate and spray dry to prepare a powder enteral diet for hemodialysis kidney disease patients.
상기 신부전증용 및 신장병 환자용 식이에서 사용한 단백질원을 포함한 주원료 중 40%에 상당하는 양을 정제수에 용해하여 표 4와 같은 비타민과 미네랄을 배합하한 다음 전체 용량을 100ml로 조정하여 균질, 포장, 리토르트 멸균 또는 살균하여 혈액투석 신부전증 환자용 액상경장영양식을 제조한다.40% of the main raw materials, including the protein source used in the diet for kidney failure and kidney disease, are dissolved in purified water, and the vitamins and minerals as shown in Table 4 are added, and then the total volume is adjusted to 100 ml, homogeneous, packaged, and retort. Sterilized or sterilized to prepare a liquid enteral culture for hemodialysis renal failure patients.
8) 만성간질환자용 분말 경장영양식8) Powder Enteral Diet for Chronic Liver Disease Patients
유청단백질가수분해물 9.72g, 케이신나트륨 6.75g, L-로이신 1.18g, L-이소로이신 1.83%, L-발린 2.03g, 덱스트린 40g, 설탕 25g, 대두유 7.35g, MCT유 3.15g, 레시친 0.35g, 그리고 프락탄식이섬유 6.45g, Bio-M 0.133g을 정제수에 용해하고 표 5와 같이 비타민과 미네랄을 첨가한 후 살균, 균질, 농축, 분무건조하여 만성간질환자용 분말 경장영양식을 조제한다.Whey Protein Hydrolyzate 9.72g, Sodium Kaycin 6.75g, L-Leucine 1.18g, L-Isoleucine 1.83%, L-Valine 2.03g, Dextrin 40g, Sugar 25g, Soybean Oil 7.35g, MCT Oil 3.15g, Lecithin 0.35g 6.45g of fructan dietary fiber and 0.133g of Bio-M are dissolved in purified water, and vitamins and minerals are added as shown in Table 5, followed by sterilization, homogenization, concentration, and spray drying to prepare a powder enteric diet for chronic liver disease patients.
9) 만성간질환자용 액상 경장영양식9) Liquid enteral culture for chronic liver disease patients
유청단백질가수분해물 2.43%, 케이신나트륨 1.69%, L-로이신 0.3%, L-이소로이신 0.46%, L-발린 0.51%, 덱스트린 10%, 설탕 6.25%, 대두유 1.84%, MCT유 0.79%, 레시친 0.1%, 프락탄식이섬유 2.53%, Bio-M 0.04%를 정제수 용해하고 표 5와 같이 비타민과 미네랄을 혼합한 다음 균질, 리토르트 멸균 또는 살균하여 만성간질환자용 액상 경장영양식을 제조한다.Whey Protein Hydrolyzate 2.43%, Caine Sodium 1.69%, L-Leucine 0.3%, L-Isoleucine 0.46%, L-Valine 0.51%, Dextrin 10%, Sugar 6.25%, Soybean Oil 1.84%, MCT Oil 0.79%, Lecithin 0.1%, fructan dietary fiber 2.53%, Bio-M 0.04% is dissolved in purified water, vitamins and minerals are mixed as shown in Table 5 and then homogeneous, retort sterilization or sterilization to prepare a liquid enteral diet for chronic liver disease patients.
10) 당뇨병 환자용 분말 경장영양식10) Powder Enteral Nutrition for Diabetics
케이신나트륨 혹은 케이신나트륨과 대두단백질 70:30 혼합물 29.63g, 덱스트린 26.72g, 프락탄식이섬유 10.13g, 카놀라유 25g, 레시친 0.35g, Bio-M 0.133g을 정제수에 용해하고 표 6과 같이 비타민과 미네랄을 혼합한 다음 살균, 균질, 농축, 분무건조하여 당뇨환자용 분말경장영양식을 제조한다.Sodium lysine or lysine protein: 29.63 g mixture of soy protein 70:30, 26.72 g dextrin, 10.13 g fructan dietary fiber, 25 g canola oil, 0.35 g lecithin, and 0.133 g Bio-M in purified water And minerals are mixed and then sterilized, homogenized, concentrated and spray-dried to prepare a powdered diet for diabetic patients.
11) 당뇨병 환자용 액상 경장영양식11) Liquid enteral culture for diabetics
케이신나트륨 혹은 케이신나트륨과 대두단백질 70:30 혼합물 7.41%, 덱스트린6.68%, 프락탄식이섬유 2.53%, 카놀라유 6.25%, 레시친 0.1%, Bio-M 0.04%을 정제수에 용해한 다음 표 6과 같이 비타민과 미네랄을 균일하게 혼합하여 전체의 용량을 100ml로 조정하여 균질, 레토르트 멸균 또는 살균하여 당뇨환자용 액상경장영양식을 제조한다.Sodium lysine or lysine and soy protein 70:30 mixture 7.41%, dextrin 6.68%, fructan dietary fiber 2.53%, canola oil 6.25%, lecithin 0.1%, Bio-M 0.04% in purified water and then as shown in Table 6 Mixing vitamins and minerals uniformly to adjust the total volume to 100ml to homogeneous, retort sterilization or sterilization to prepare a liquid entertaining diet for diabetic patients.
12) 소화기질환 환자용 경장영양식12) Enteral culture for patients with digestive diseases
호박산처리 변성옥수수전분13.2g을 정제수에 용해하여 분산시킨 다음 80℃까지 서서히 가온한 후 덱스트린 35.6g, 카놀라유 4.34g, MCT유 1.86g, L-아르기닌1.08g,프락탄식이섬유 4.21g, Bio-M 0.133g을 용해하여 혼합한 다음 표 7의 비타민과 미네랄을 혼합하여 균질, 살균, 농축, 분무건조한다. 그리고 분무건조된 분말과 케이신가수분해물 35%와 밀단백가수분해물 65%의 비율로 혼합한 단백질이 20%이상, 설탕을 탄수화물의 20%이상 되게 혼합하여 소화기질환 환자용 경장영양식을 조제한다.13.2 g of succinic acid-modified maize starch was dissolved in purified water, dispersed, and then slowly warmed up to 80 ° C., followed by 35.6 g of dextrin, 4.34 g of canola oil, 1.86 g of MCT oil, 1.08 g of L-arginine, and 4.21 g of fructan dietary fiber. Dissolve and mix 0.133 g of M, then mix the vitamins and minerals in Table 7 to homogenize, sterilize, concentrate, and spray dry. In addition, spray-dried powder, a mixture of 35% casein hydrolyzate and 65% wheat protein hydrolyzate, is mixed with 20% or more of sugar and 20% or more of carbohydrates.
13) 소취용 제품13) Deodorizing Products
송이버섯추출물(Bio-M 성분) 40%, 덱스트린 40% 그리고 설탕 20%를 함유하는 타블렛 또는 분말로 된 제품으로 이 제품은 대장암 환자와 같이 분변의 배설기능이 정상적이지 못한 환자들의 장관소화물이나 분변으로부터 악취의 발생을 최대한 억제할 수 있도록 만들어진 소취용 제품이다.It is a tablet or powder product containing 40% of pine mushroom extract (Bio-M), 40% dextrin and 20% sugar.This product is used for intestinal digestion in patients with abnormal fecal excretion, such as colon cancer. It is a deodorizing product designed to minimize the occurrence of odor from feces.
이상과 같이 본 발명은 단백질, 지방, 탄수화물의 열량비율을 일반환자의 식사대용 및 영양간식으로 이용할 수 있는 경장영양식과 신부전증 환자, 만성간질환 환자, 당뇨환자, 소화기질환을 가지고 있는 환자들의 특정한 영양요구량에 적합하게 영양소를 공급해 주도록 조제된 것과 송이버섯추출물과 프럭탄 식이섬유를 배합하여 환자의 장내 세균총 중에서 비피도박테리아의 증식을 선택적으로 촉진시켜 배변을 용이하게 하고 분변취를 포함한 음식물의 소화에서 유래하는 냄새의 발생을 최한 억제시킬 수 있는 경장영양식의 개발이다. 그리고 소취 제품으로 본 발명에 포함된제품은 영양적으로 완전한 제품은 아니며 단지 1일 3-4회의 섭취에 의해서 악취의 발생을 억제해 주도록 설계된 제품이다.As described above, the present invention provides specific nutrition of patients who have caloric ratios of protein, fat, and carbohydrates as food substitutes and nutritional snacks for general patients, patients with renal failure, patients with chronic liver disease, patients with diabetes, and digestive diseases. Formulated to provide nutrients according to the requirements, and the combination of matsutake extract and fructan dietary fiber to selectively promote the growth of Bifidobacteria in the intestinal flora of the patient, facilitating defecation and digestion of food including feces It is the development of enteral culture that can minimize the occurrence of the resulting odor. And the product contained in the present invention as a deodorant product is not a nutritionally complete product is a product designed to suppress the occurrence of odor only by ingestion only 3-4 times a day.
본 발명은 송이버섯(Agaricus bisporus)과육의 친수성 용매추출물과 프럭탄 식이섬유(fructan fiber)를 포함하는 경장영양식을 제공하며, 특히, 신부전증환자, 신장병환자, 만성간질환자, 당뇨병환자용 또는 소화기질환자용 영양식과 같은 환자용 특수영양식품 또는 건강보조식품을 제공함으로써, 경장 영양식을 섭취한 경우에 분변취 및 설사발생을 방지 또는 최소화하는 장점이 있다.The present invention provides an enteral diet comprising a hydrophilic solvent extract of Agaricus bisporus flesh and fructan fiber, particularly for kidney failure patients, kidney disease patients, chronic liver disease patients, diabetic patients or digestive disease patients. By providing a special nutritional supplement or health supplement for patients, such as nutrition, there is an advantage of preventing or minimizing the occurrence of feces and diarrhea when ingested enteric nutrition.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0060079A KR100421178B1 (en) | 2000-10-12 | 2000-10-12 | Enteral formula suppressing the occurrence of the odor of stool and diarrhea |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0060079A KR100421178B1 (en) | 2000-10-12 | 2000-10-12 | Enteral formula suppressing the occurrence of the odor of stool and diarrhea |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020029232A true KR20020029232A (en) | 2002-04-18 |
KR100421178B1 KR100421178B1 (en) | 2004-03-04 |
Family
ID=19693177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0060079A KR100421178B1 (en) | 2000-10-12 | 2000-10-12 | Enteral formula suppressing the occurrence of the odor of stool and diarrhea |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100421178B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101732717B1 (en) | 2015-01-23 | 2017-05-04 | 주식회사 정식품 | Medical food composition for immunity |
JP7295269B2 (en) * | 2019-11-29 | 2023-06-20 | 森永乳業株式会社 | Composition for enteral intake |
KR102608047B1 (en) | 2020-12-29 | 2023-12-01 | 주식회사 우제아이엠 | Balanced nutrition included food composition for preventing or improving reflux esophageal disease or functional dyspepsia |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH069488B2 (en) * | 1989-07-11 | 1994-02-09 | 株式会社紀文 | Kneaded product with dietary fiber |
BE1005438A4 (en) * | 1991-10-04 | 1993-07-27 | Raffinerie Tirlemontoise Sa | Cream compositions containing fructan, their method of preparation and use compositions. |
JPH05238945A (en) * | 1992-02-26 | 1993-09-17 | Eisai Co Ltd | Intestinal environment-improving agent |
JPH1099055A (en) * | 1996-09-26 | 1998-04-21 | Akiyo Akamatsu | Production of smell-removed food product |
JP3111378B2 (en) * | 1996-11-28 | 2000-11-20 | 福井県 | Method for producing fructan as water-soluble dietary fiber |
KR100249357B1 (en) * | 1998-03-27 | 2000-03-15 | 한수길 | A compsition of chewing gum removing foul odor |
JPH11332513A (en) * | 1998-05-29 | 1999-12-07 | Beech Nut Nutrition Corp | Baby food composition containing fructan and its production |
-
2000
- 2000-10-12 KR KR10-2000-0060079A patent/KR100421178B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR100421178B1 (en) | 2004-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2289955C2 (en) | Nutritional formula for prophylaxis and treatment of immune conditions | |
KR101361379B1 (en) | Nutrient composition | |
CN106473153A (en) | Full nutrition formula food and preparation method thereof | |
JP4553604B2 (en) | Function enhancing composition for general food, health functional food or health supplement and method thereof | |
KR20070054739A (en) | Total enteral nutritious composition | |
AU2002221860A1 (en) | Nutritional composition for an immune condition | |
EP3164124A1 (en) | Amino acid based diet with improved taste | |
CN107440088A (en) | Improve operation, the nutrients and preparation method thereof of chemicotherapy tumor patient immunity | |
CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
CN108450938A (en) | A kind of fat reducing meal replacement powder and preparation method thereof | |
JP2006514540A (en) | Calcium absorption improver | |
JP4596513B2 (en) | Nutritional composition | |
CN108936595A (en) | Colon cancer nutraceutical and preparation method thereof | |
JPH07194316A (en) | Calcium absorbefacient composition and calcium absorbefacient additive containing water-soluble chitosan | |
Mellanby | A British Medical Association lecture on diet and disease. With special reference to the teeth, lungs, and pre-natal feeding | |
KR100421178B1 (en) | Enteral formula suppressing the occurrence of the odor of stool and diarrhea | |
US20060210606A1 (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood | |
JP2001316278A (en) | Liquid enteral nutrition composition | |
JP2750467B2 (en) | Peptide mixture and enteral nutrition composition | |
CN108851037A (en) | A kind of preparation method and its usage of nephrotic syndrome wholefood | |
JP4694053B2 (en) | Infant nutrition composition | |
JP2808281B2 (en) | Protein foods and physiological supplements | |
RU2311038C2 (en) | Product for enteral feeding | |
JP2001233783A (en) | Preoperative nutrient agent | |
JP2003246753A (en) | Intestinal flora improver and food and drink |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20091229 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20121218 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20151130 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20181220 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20191209 Year of fee payment: 17 |